Andere Sprachen Travere Therapeutics, Inc.

Aktien

A2QHYP

US89422G1076

TVTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:32:22 18.06.2024			% 5 Tage	% 1. Jan.
7,14 ^USD	-2,59 %		+0,71 %	-20,80 %

05.06.	Transcript : Travere Therapeutics, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
15.05.	Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	11.06.
Travere Therapeutics : Corporate Overview – May 2024	16.05.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15.05.
Travere Therapeutics : Equity Incentive Plan - Form 8-K	13.05.
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress	09.05.
Travere Therapeutics to Present at Upcoming Investor Conferences	08.05.
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
Travere: Q1 Earnings Snapshot	06.05.
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M	06.05.
Travere Therapeutics Reports First Quarter 2024 Financial Results	06.05.
Travere Therapeutics to Report First Quarter 2024 Financial Results	29.04.
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy	25.04.
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	24.04.
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24.04.
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	24.04.
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24.04.
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	24.04.
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International	04.04.
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association	03.04.
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	03.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Travere Therapeutics, Inc.

Aktien

A2QHYP

US89422G1076

TVTX

Andere Sprachen

Filter